How does finerenone improve diabetic kidney disease in patients with type 2 diabetes, chronic kidney disease, and albuminuria despite ACE inhibitor or ARB therapy?

Finerenone Improves Diabetic Kidney Disease Through Nonsteroidal Mineralocorticoid Receptor Antagonism

Finerenone reduces both kidney disease progression and cardiovascular events in patients with type 2 diabetes and chronic kidney disease by blocking mineralocorticoid receptors, thereby reducing inflammation, fibrosis, and albuminuria—effects that are additive to standard ACE inhibitor/ARB therapy.

Mechanism of Action and Clinical Benefits

Finerenone is a nonsteroidal mineralocorticoid receptor antagonist (ns-MRA) that works differently from traditional steroidal MRAs like spironolactone 1. Its primary mechanisms include:

Direct Renal and Cardiovascular Protection

• Reduces albuminuria significantly: Finerenone decreases urinary albumin-to-creatinine ratio (UACR) by approximately 30-40%, with this reduction mediating much of the treatment effect on kidney and cardiovascular outcomes 2, 3, 4
• Slows kidney function decline: Improves eGFR slope from approximately -5 to -0.6 mL/min/1.73 m²/year in real-world studies 3
• Anti-inflammatory and antifibrotic effects: Targets the underlying pathophysiology of diabetic kidney disease beyond blood pressure control 4

Evidence from Landmark Trials

The FIDELIO-DKD trial (advanced CKD population) demonstrated:

• 18% reduction in composite kidney outcome (HR 0.82,95% CI 0.73-0.93, P<0.001) 2
• 14% reduction in cardiovascular events (HR 0.86,95% CI 0.75-0.99, P<0.03) 2

The FIGARO-DKD trial (earlier CKD stages) showed:

• 13% reduction in cardiovascular death, MI, stroke, or heart failure hospitalization (HR 0.87,95% CI 0.76-0.98, P<0.03) 2
• 36% reduction in end-stage kidney disease (HR 0.64,95% CI 0.41-0.995) 2

The FIDELITY pooled analysis (13,026 patients) confirmed consistent benefits across the CKD spectrum:

• 14% cardiovascular risk reduction (HR 0.86,95% CI 0.78-0.95, P=0.0018) 5
• 23% kidney failure risk reduction (HR 0.77,95% CI 0.67-0.88, P=0.0002) 5

Clinical Implementation Algorithm

Patient Selection Criteria

Initiate finerenone when ALL of the following are met 1:

1. Type 2 diabetes with CKD
2. Persistent albuminuria (ACR ≥30 mg/g) despite maximum tolerated ACE inhibitor or ARB therapy
3. eGFR ≥25 mL/min/1.73 m²
4. Serum potassium ≤4.8 mmol/L (trial criteria) or ≤5.0 mmol/L (FDA label)

Dosing Strategy

Initial dose based on eGFR 1:

• eGFR >60 mL/min/1.73 m²: Start 20 mg once daily
• eGFR 25-60 mL/min/1.73 m²: Start 10 mg once daily

Dose titration after 4 weeks 1:

• If potassium <4.8 mmol/L and eGFR stable: Increase 10 mg to 20 mg daily
• Continue 20 mg if potassium remains ≤5.5 mmol/L

Potassium Monitoring Protocol

Critical monitoring schedule 1:

• Check potassium 4 weeks after initiation or dose change
• Continue regular monitoring during treatment

Management of hyperkalemia:

• Potassium >5.5 mmol/L: Withhold finerenone
• Restart at 10 mg daily when potassium ≤5.0 mmol/L
• Discontinue permanently if recurrent problematic hyperkalemia occurs

Real-world data show hyperkalemia leading to discontinuation occurs in only 1.2-1.7% of patients, with higher risk in those with eGFR <30 mL/min/1.73 m² 2, 6, 7.

Combination with Other Therapies

Additive Effects with SGLT2 Inhibitors

Finerenone can and should be combined with SGLT2 inhibitors when both are indicated 1, 8. The mechanisms are complementary:

• SGLT2 inhibitors may reduce hyperkalemia risk when used with finerenone
• Benefits appear additive based on trial subgroup analyses (4.5% of FIDELIO-DKD patients were on SGLT2 inhibitors) 2
• Both target different pathways: SGLT2i reduce intraglomerular pressure; finerenone blocks mineralocorticoid-mediated inflammation/fibrosis

Relationship to ACE Inhibitors/ARBs

Finerenone is NOT a replacement for ACE inhibitors/ARBs—it is an add-on therapy 1. However:

• Albuminuria reduction is more pronounced with concurrent ACEi/ARB use (62% reduction vs. 15% reduction without) 9
• Finerenone monotherapy may be considered when ACEi/ARB cannot be tolerated, though efficacy is reduced 9
• Never combine ACEi + ARB + finerenone—this increases hyperkalemia and AKI risk without added benefit 1

Common Pitfalls and Practical Considerations

Key Safety Concerns

1. Hyperkalemia risk is highest with:

   • eGFR <30 mL/min/1.73 m² (37.5% incidence in one study) 7
   • Concurrent ACEi/ARB use (necessary but increases risk) 9
   • Inadequate potassium monitoring

2. Initial eGFR decline is expected: A transient decrease in eGFR occurs early but does not indicate treatment failure—this is hemodynamic and similar to ACEi/ARB initiation 3

3. Continue therapy even if eGFR falls <25 mL/min/1.73 m² during treatment, as long as potassium remains acceptable and drug is tolerated 1

Who Benefits Most

Highest priority patients 1, 10:

• Persistent albuminuria despite ACEi/ARB and SGLT2 inhibitor therapy
• eGFR 25-60 mL/min/1.73 m² with significant albuminuria (ACR ≥300 mg/g)
• Patients at high cardiovascular risk with any level of albuminuria

Guideline Recommendations

The 2022 ADA/KDIGO consensus and 2023 ADA Standards strongly recommend 1, 2, 1:

• Adding a nonsteroidal MRA (finerenone) to treatment regimens for patients with type 2 diabetes, eGFR ≥25 mL/min/1.73 m², normal potassium, and albuminuria (ACR ≥30 mg/g) despite maximum tolerated RAS inhibitor
• This represents a paradigm shift toward comprehensive cardiorenal protection using multiple complementary mechanisms

The 2025 KDOQI commentary prioritizes SGLT2 inhibitors over finerenone as the next step after ACEi/ARB, but emphasizes finerenone should be added if albuminuria persists despite SGLT2 inhibitor therapy 10.